QCG
AMRI

Quadrant Capital Group’s Albany Molecular Research Inc AMRI Stock Holding History

Quadrant Capital Group’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-51
Closed – – 2133
2016
Q2 		$0 Hold
51
– – ﹤0.01% 2149
2016
Q1 		$0 Buy
+51
New +$799 ﹤0.01% 2134

Other funds holding AMRI

PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
OWP
Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Quadrant Capital Group's AMRI Position: Q3 2016 in Review

Quadrant Capital Group sold out of Albany Molecular Research Inc (AMRI) in Q3 2016, closing a stake of 51 shares.

Quadrant Capital Group first reported a position in AMRI in Q1 2016 and held it in 2 quarters. The position peaked at $0 in Q2 2016. 137 funds tracked by Wall St. Rank hold AMRI as of Q3 2016.

  • Quadrant Capital Group reported no remaining Albany Molecular Research Inc position as of Q3 2016 after selling out during the quarter.
  • Quadrant Capital Group sold 51 Albany Molecular Research Inc shares in Q3 2016.
  • Quadrant Capital Group first reported a position in Albany Molecular Research Inc in Q1 2016 and held it in 2 quarters.
  • Quadrant Capital Group's Albany Molecular Research Inc position peaked at $0 in Q2 2016.
  • 137 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2016.

Based on Quadrant Capital Group's 13F filing for Q3 2016, filed 25 Oct 2016.